MD Biosciences Expansion To Increase Capacity In Pre-Clinical Drug Discovery Services And Products For Inflammatory And Neurological Diseases

Main Category: Neurology / Neuroscience
Article Date: 06 Oct 2009 - 17:00 PDT

email to a friend   printer friendly   view / write opinions

MD Biosciences (MDB), a contract research organization offering pre-clinical services and products in support of drug discovery for inflammatory and neurological diseases, relocated its U.S. office from 1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on October 3, 2009. The new location equips MD Biosciences with more lab space, allowing for increased capacity for in vitro services and product development and manufacturing to increase product offering.

Eddie Moradian, President of MD Biosciences states, "At MD Biosciences, we have always promised our clients that we will meet their needs now and in the future; our expansion ensures that commitment. We doubled our lab space so that we are able to provide 150 percent more services and increase product development by 130 percent in the coming year in comparison with the last.

"Our relocation is just one step of many in the endeavor to continue to offer the highest quality services and products in assisting our customers in meeting their objectives. Future projections include adding more highly specialized scientists to our team and increasing our focus on our available products and proprietary reagents."

Source
MD Biosciences